Contact Information


Post-Doctoral Fellow, Scripps Institution of Oceanography, UCSD, 2012
Post-Doctoral Fellow, Smithsonian Tropical Research Institute, Panama, 2012
Ph.D., Medicinal and Natural Products Chemistry, University of Iowa, 2007
B.S, Chemistry, Mercyhurst College, 2003

Profile Information

Publications Since 2006

Harding, W.W.; Schmidt, M.; Tidgewell, K.; Kannan, P.; Holden, K.G.; Gilmour, B.; Navarro, H.; Rothman, R.B.; Prisinzano, T.E. Synthetic Studies of Neoclerodane Diterpenes from Salvia divinorum: Semisynthesis of Salvinicins A and B and Other Chemical Transformations of Salvinorin A. J. Nat. Prod. 2006 (69): 107-112.

Harding, W.W.; Schmidt, M.D.; Tidgewell, K.; Kannan, P.; Holden, K.G.; Dersch, C.M.; Rothman, R.B.; Prisinzano, T.E. Synthetic Studies of Neoclerodane Diterpenes from Salvia divinorum: Selective Modification of the Furan Ring. Bio. Med. Chem. Letters. 2006 (16): 3170-3174.

Tidgewell, K.; Harding, W.W.; Schmidt, M.D.; Lozama, A.; Cobb, H.; Shah, K.; Kannan, P.; Dersch, C.M.; Parrish, D.; Deschamps, J.R.; Rothman, R.B.; Prisinzano, T.E. Synthesis of Salvinorin A Analogues as Opioid Receptor Probes. J.Nat.Prod. 2006 (69): 914-918.

Rothman, R.B.; Wang, X.; Tidgewell, K.; Bohn, L.M.; Prisinzano, T.E.; Partilla, J. A Comparison of Non-Internalizing (Herkinorin) and Internalizing (Damgo) Mu Opioid Agonists on Cellular Markers Related to Opioid Tolerance and Dependence. Synapse. 2007 61(3): 166-175.

Butelman, E.R.; Mandau, M.; Tidgewell, K.; Prisinzano, T.E.; Yuferov, V.; Kreek, M.J. Effects of salvinorin A, a Description: {kappa}-opioid hallucinogen, on a neuroendocrine biomarker assay in non-human primates with high Description: {kappa}-receptor homology to humans. J. Pharm. Exp. Ther. 2007 320(1): 300-306.

Groer, C.E.; Tidgewell, K.; Moyer, R.A.; Harding, W.W.; Rothman, R.B.; Prisinzano, T.E.; Bohn, L.M. An Opioid Agonist that Does Not Induce Mu Opioid Receptor - Arrestin Interactions or Receptor Internalization. Mol Pharm. 2007 (71): 549-557.

Rothman, R.B.; Murphy, D.L.; Xu, H.; Godin, J.A.; Dersch, C.M.; Partilla, J.S.; Tidgewell, K.; Schmidt, M.; Prisinzano, T.E. Salvinorin A: Allosteric Interactions at the Mu Opioid Receptor. J. Pharm. Exp. Ther. 2007 320(2): 801-810.

Holden, K.G.; Tidgewell, K.; Marquam, A.; Rothman, R.B.; Navarro, H.; Prisinzano, T.E. Synthetic studies of neoclerodane diterpenes from Salvia divinorum: exploration of the 1-position. Bio. Med. Chem. Letters. 2007 (17): 6111-6115.

Tidgewell, K.; Groer, C.; Harding, W.W.; Lozama, A.; Schmidt, M.; Marquam, A.; Hiemstra, J.; Partilla, J.S.; Dersch, C.M.; Rothman, R.B.; Bohn, L.M.; Prisinzano, T.E. Herkinorin analogues with differential beta-arrestin-2 interactions. J. Med. Chem. 2008 51(8): 2421-2431.

Balunas, M.J.; Linington, R.G.; Tidgewell, K.; Fenner, A.M.; Ureña, L.D.; Togna, G.D.; Kyle, D.E.; Gerwick, W.H. Dragonamide E, a modified linear lipopeptide from Lyngbya majuscula with antileishmanial activity. J. Nat. Prod. 2010 73(1): 60-66.

Gutiérrez, M.; Tidgewell, K.; Capson, T.L.; Engene, N.; Almanza, A.; Schemies, J.; Jung, M.; Gerwick W.H. Malyngolide Dimer, a Bioactive Symmetric Cyclodepside from the Panamanian Marine Cyanobacterium Lyngbya majuscula. J. Nat. Prod. 2010 73(4): 709-11.

Tidgewell, K.; Engene, N.; Byrum, T.; Media, J.; Valeriote, F.A.; Gerwick, W.H. Diversification of a Modular Natural Product Pathway: Production of Apratoxins F and G, Two Cytotoxic Cyclic Depsipeptides from a Palmyra Collection of Lyngbya bouillonii. ChemBioChem. 2010 11(10): 1458-66.

Tidgewell, K.; Clark, B.R.; Gerwick, W.H. The Natural Products Chemistry of Cyanobacteria. In Comprehensive Natural Products Chemistry 2nd Ed.; Moore, B., Crews, P., Eds.; Elsevier: Oxford, 2010; Vol 2; p141-188.

Lamb, K.; Tidgewell, K.; Simpson, D.S.; Bohn, L.M.; Prisinzano, T.E. Antinociceptive effects of herkinorin, a MOP receptor agonist derived from salvinorin A in the formalin test in rats: new concepts in mu opioid receptor pharmacology: from a symposium on new concepts in mu-opioid pharmacology. Drug Alcohol Depend. 2012 121(3): 181-8.

Balunas, M.J.; Grosso, M.F.; Villa, F.A.; Engene, N.; McPhail, K.L.; Tidgewell, K.; Pineda R, L.M.; Gerwick, L.; Spadafora, C.; Kyle, D.E.; Gerwick, W.H. Coibacins A-D, New Anti-leishmanial Polyketides with Intriguing Biosynthetic Origins. Org Lett. 2012 14(15): 3878-81.


Presentations Since 2006

Kevin J. Tidgewell, Center for Marine Biotechnology and Biomedicine, Scripps Institute of Oceanography, University of California at San Diego, La Jolla, CA; Herkinorin: An Antinociceptive Derived from Salvinorin A with Altered Cellular Signaling, for the Natural Products Affinity Group The Salk Institute, La Jolla, CA, February 22, 2008.

Kevin Tidgewell, Drug Discovery from Marine Cyanobacteria, for BAMBI The Smithsonian Tropical Research Institute, Barro Colorado Island, Panamá, Panama, February 10, 2011.

Kevin Tidgewell, Drug Discovery from Panamanian Cyanobacteria, for STRI Fellows Symposium, Ancón, Panamá, Panama, March 18, 2011.

Kevin Tidgewell, Novel Treatments for Neglected Diseases from Marine Cyanobacteria, for Curso de Quimica de Productos Naturales: Realidades, Nuevas Tenencias, y Retos, INDICASAT, Ciúdad del Saber, Clayton, Panama, May 30 - June 2, 2011.

GPSC 696 – Medicinal Chemistry Graduate Student Seminar

PHBM 350 – Biochemistry I: Peptides and Carbohydrate Metabolism

2005–08: AFPE Pre-Doctoral Fellow

6/2006: National Medicinal Chemistry Symposium Travel Award

7/2007: International Narcotics Research Conference Travel Award

2008–10: Growth Regulation and Oncogenesis Training Grant Fellow

7/2010: American Society of Pharmacognosy Travel Grant for Active Members

The Tidgewell lab works in the fields of Medicinal and Natural Products Chemistry. Our work focuses on the discovery of novel ligands from marine cyanobacteria for GPCR targets. Projects in the lab range from extraction, isolation and structure elucidation of novel leads to semi-synthetic medicinal chemistry lead optimization. The major focus of our work is on pain and addiction with the broader scope being GPCRs involved in regulating CNS processes and other complex disease states.